<DOC>
	<DOCNO>NCT02057445</DOCNO>
	<brief_summary>The administration allogeneic third party derive LMP specific-CTLs ( special peripheral blood cell another person ) make specific fight EBV infection ) Children , Adolescents Young Adults ( CAYA ) EBV-associated refractory relapse lymphoma feasible ( able do ) , safe well tolerate ( unexpected serious event occur ) . In addition , potential donor EBV positive enrol donate peripheral blood help build bank specific EBV fighting cell line .</brief_summary>
	<brief_title>3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes EBV-Associated Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>Patient must least 1 year age . Patient patient 's legally authorized guardian must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) , must sign informed consent accordance institutional policy approve U.S. Department Health Human Services . Patients investigational therapy one month prior entry study . Patient must adequate organ function : Adequate renal function define : Serum creatinine &lt; 2.0 x normal , Creatinine clearance radioisotope GFR &gt; 40 ml/min/m2 &gt; 60 ml/min/1.73 m2 equivalent GFR determine institutional normal range Adequate liver function define : Total bilirubin &lt; 2.0 x normal ; SGOT ( AST ) SGPT ( ALT ) &lt; 5.0 x normal Adequate pulmonary function define : Pulse oximetry &gt; 94 % room air . Lansky ( &lt; 16yr ) Karnofsky ( &gt; 16 yr ) performance status ≥ 50 % Life expenctancy ≥ 6 week . Women child bearing age require negative urine pregnancy test . Clinical status enrollment allow taper steroid le 0.5mg/kg/day prednisone time treatment . 4.5 Disease Status ( Eligibility ) 4.5.1 Any patient , one follow EBVpositive type II latency associate disorder , regardless histological subtype : Hodgkin lymphoma NonHodgkin lymphoma Lymphoproliferative disorder Severe chronic active EBV infection syndrome ( SCAEBV ) , define high EBV viral load plasma PBMC ( &gt; 4000 genome per μg PBMC DNA ) and/or biopsy tissue positive EBV The disease need one following stage : At diagnosis would unable receive conventional chemotherapy first relapse AND patient candidate HSCT Partial response conventional therapy . Refractory conventional therapy his/her condition . In second subsequent relapse . Residual disease autologous , syngeneic allogeneic HSCT . All patient enter study ideally tumor tissue original diagnostic specimen and/or relapse review centrally confirmation EBV positive disease . If specimen available , local pathology report document EBV positivity acceptable . Appropriate immunophenotyping confirm diagnosis perform . In addition , situ hybridization EBV ( LMP1 , and/or EBER positivity ) perform . All central morphologic analysis immunohistochemical/insitu hybridization stain perform laboratory Sherrie Perkins Rodney Miles University Utah . Donor Eligibility LMPCTL Third Party Banking ( Aim 2.1.2 ) Donor must HIV negative . Donors must adequate hematopoietic function define absolute neutrophil count &gt; 1000/mm3 , hemoglobin &gt; 10 g/dl , platelet count &gt; 50,000/mm3 EBV IgG seropositive . Donors peripheral blood collect LMP specific CTL production . A minimum 60 cc peripheral blood x 2 total maximum amount blood 120cc , collect donor ( subject must least 12 kg 24 pound ) . ( See Appendix B ) For donor &lt; 18 year maximum 3cc/kg blood take 8 week period . For donor undergo stem cell collection , peripheral blood LMP specific CTL production collect prior stem cell collection without specific day specification . Donor eligibility must meet criterion per 21 CFR 1271 . Currently receive investigational agent receive tumor vaccine within previous 4 week . Active acute grade IIIIV graftversushost disease . Severe refractory intercurrent infection EBV . Received alemtuzumab antiTcell antibody within 28 day . HIV seropositivity . Pregnancy ( due unknown effect therapy fetus ) lactation . Patients PTLD post solid organ transplantation eligible COG PTLD LMP/CTL protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cellular therapy</keyword>
	<keyword>lymphoma</keyword>
	<keyword>lymphoproliferative disorder</keyword>
</DOC>